Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ebselen,Silver Ions
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Mikael Lonn
Deal Size : $2.4 million
Deal Type : Series A Financing
TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic
Details : The financing will support the development of EbsArgent, the company's first-in-class bactericidal antibiotic for urinary tract infections (UTIs) caused by antibiotic-resistant bacteria.
Product Name : EbsArgent
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 30, 2024
Lead Product(s) : Ebselen,Silver Ions
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Mikael Lonn
Deal Size : $2.4 million
Deal Type : Series A Financing
Reset All
